Advertisement
Advertisement

Archive

Update on lipids, inflammation and atherothrombosis
Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Contemporary issues in atherothrombosis
DOI: http://dx.doi.org/10.1160/THS10-11-0717
Issue: 2011: 105/Supplement 1
Pages: S34-S42

Archive
Issue
Article
References

  1. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88: 756-762. DOI:10.1161/hh0801.089861
  2. Vidal F, Colome C, Martinez-Gonzalez J, et al. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. Eur J Biochem 1998; 252: 378-384. DOI:10.1046/j.1432-1327.1998.2520378.x
  3. Liao JK, Shin WS, Lee WY, et al. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324. DOI:10.1074/jbc.270.1.319
  4. Blair A, Shaul PW, Yuhanna IS, et al. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 1999; 274: 32512-32519. DOI:10.1074/jbc.274.45.32512
  5. Badimon L, Martinez-Gonzalez J, Llorente-Cortes V, et al. Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 2006; 6: 439-456. DOI:10.2174/156652406778018725
  6. Badimon L, Vilahur G, Padro T. Lipoproteins, platelets and atherothrombosis. Rev Esp Cardiol 2009; 62: 1161-1178. DOI:10.1016/S0300-8932(09)72385-1
  7. Camejo G, Hurt-Camejo E, Wiklund O, et al. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998; 139: 205-222. DOI:10.1016/S0021-9150(98)00107-5
  8. Csiszar A, Wang M, Lakatta EG, et al. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol 2008; 105: 1333-1341. DOI:10.1152/japplphysiol.90470.2008
  9. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874. DOI:10.1038/nature01323
  10. Simionescu M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 266-274. DOI:10.1161/01.ATV.0000253884.13901.e4
  11. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 2007; 7: 467-477. DOI:10.1038/nri2096
  12. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205. DOI:10.1172/JCI29950
  13. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527-2534.
  14. Hristov M, Leyendecker T, Schuhmann C, et al. Circulating monocyte subsets and cardiovascular risk factors in coronary artery disease. Thromb Haemost 2010; 104: 412-414. DOI:10.1160/TH10-01-0069
  15. Rogacev KS, Seiler S, Zawada AM, et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011; 32: 84-92. DOI:10.1093/eurheartj/ehq371
  16. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1424-1432. DOI:10.1161/ATVBAHA.108.180521
  17. Sunderkotter C, Nikolic T, Dillon MJ, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004; 172: 4410-4417.
  18. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317: 666-670. DOI:10.1126/science.1142883
  19. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009; 27: 165-197. DOI:10.1146/annurev.immunol.021908.132620
  20. Lindstedt KA, Kovanen PT. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr Opin Lipidol 2004; 15: 567-573. DOI:10.1097/00041433-200410000-00011
  21. Collot-Teixeira S, Martin J, McDermott-Roe C, et al. CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007; 75: 468-477. DOI:10.1016/j.cardiores.2007.03.010
  22. Llorente-Cortes V, Royo T, Otero-Vinas M, et al. Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. Cardiovasc Res 2007; 74: 526-536. DOI:10.1016/j.cardiores.2007.02.020
  23. Suzuki H, Kurihara Y, Takeya M, et al. The multiple roles of macrophage scavenger receptors (MSR) in vivo: resistance to atherosclerosis and susceptibility to infection in MSR knockout mice. J Atheroscler Thromb 1997; 4: 1-11.
  24. Saad AF, Virella G, Chassereau C, et al. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J Lipid Res 2006; 47: 1975-1983. DOI:10.1194/jlr.M600064-JLR200
  25. Choi SH, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res 2009; 104: 1355-1363. DOI:10.1161/CIRCRESAHA.108.192880
  26. Miller YI, Choi SH, Fang L, et al. Toll-like receptor-4 and lipoprotein accumulation in macrophages. Trends Cardiovasc Med 2009; 19: 227-232. DOI:10.1016/j.tcm.2010.02.001
  27. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-3108. DOI:10.1161/hc5001.100631
  28. Mullick AE, Soldau K, Kiosses WB, et al. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med 2008; 205: 373-383. DOI:10.1084/jem.20071096
  29. Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. Antioxid Redox Signal 2009; 11: 2333-2339. DOI:10.1089/ars.2009.2469
  30. Tsukano H, Gotoh T, Endo M, et al. The endoplasmic reticulum stress-C/EBP homologous protein pathway-mediated apoptosis in macrophages contributes to the instability of atherosclerotic plaques. Arterioscler Thromb Vasc Biol 30: 1925-1932.
  31. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, et al. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004; 110: 452-459. DOI:10.1161/01.CIR.0000136032.40666.3D
  32. Camino-Lopez S, Llorente-Cortes V, Sendra J, et al. Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells. Cardiovasc Res 2007; 73: 208-216. DOI:10.1016/j.cardiores.2006.10.017
  33. Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res 2001; 38: 113-119. DOI:10.1159/000051038
  34. Padro T, Pena E, Garcia-Arguinzonis M, et al. Low-density lipoproteins impair migration of human coronary vascular smooth muscle cells and induce changes in the proteomic profile of myosin light chain. Cardiovasc Res 2008; 77: 211-220. DOI:10.1093/cvr/cvm045
  35. Badimon JJ, Santos-Gallego CG, Badimon L. [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]. Rev Esp Cardiol 2010; 63 (Suppl 2): 20-35. DOI:10.1016/S0300-8932(10)70150-0
  36. Choi BG, Vilahur G, Yadegar D, et al. The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med 2006; 6: 571-587. DOI:10.2174/156652406778018590
  37. Cimmino G, Ibanez B, Vilahur G, et al. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I (Milano). J Cell Mol Med 2009; 13: 3226-3235. DOI:10.1111/j.1582-4934.2008.00614.x
  38. Stenvinkel P, Karimi M, Johansson S, et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? J Intern Med 2007; 261: 488-499. DOI:10.1111/j.1365-2796.2007.01777.x
  39. Sharma P, Kumar J, Garg G, et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol 2008; 27: 357-365. DOI:10.1089/dna.2007.0694
  40. Vickers KC, Remaley AT. MicroRNAs in atherosclerosis and lipoprotein metabolism. Curr Opin Endocrinol Diabetes Obes 2010; 17: 150-155. DOI:10.1097/MED.0b013e32833727a1
  41. Harris TA, Yamakuchi M, Ferlito M, et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 2008; 105: 1516-1521. DOI:10.1073/pnas.0707493105
  42. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81. DOI:10.1126/scisignal.2000610
  43. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710-1713. DOI:10.1126/science.1174381
  44. Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. Curr Drug Targets 2010; 11: 943-949. DOI:10.2174/138945010791591313
  45. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989; 84: 1134-1144. DOI:10.1172/JCI114277
  46. Molins B, Pena E, Padro T, et al. Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin. Arterioscler Thromb Vasc Biol 30: 1246-1252.
  47. Yaron G, Brill A, Dashevsky O, et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol 2006; 134: 426-431. DOI:10.1111/j.1365-2141.2006.06198.x
  48. Molins B, Pena E, Vilahur G, et al. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008; 28: 2239-2246. DOI:10.1161/ATVBAHA.108.174359
  49. Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009; 105: 128-137. DOI:10.1161/CIRCRESAHA.108.190611
  50. Badimon L, Badimon JJ, Vilahur G, et al. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb 2002; 32: 225-231. DOI:10.1159/000073571
  51. Parise L, Smyth S, Coller B. Platelet morphology, biochemistry, and function. McGraw-Hill Professional, New York; 2005.
  52. Viles-Gonzalez JF, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. Eur Heart J 2005; 26: 1557-1561. DOI:10.1093/eurheartj/ehi175
  53. Vilahur G, Casani L, Badimon L. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 2007; 98: 662-669.
  54. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250. DOI:10.1056/NEJM199201233260406
  55. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-318. DOI:10.1056/NEJM199201303260506
  56. Butt E, Gambaryan S, Gottfert N, et al. Actin binding of human LIM and SH3 protein is regulated by cGMP- and cAMP-dependent protein kinase phosphorylation on serine 146. J Biol Chem 2003; 278: 15601-15607. DOI:10.1074/jbc.M209009200
  57. Owens AP, 3rd, Mackman N. Tissue factor and thrombosis: The clot starts here. Thromb Haemost 104: 432-439.
  58. Hemker HC, van Rijn JL, Rosing J, et al. Platelet membrane involvement in blood coagulation. Blood Cells 1983; 9: 303-317.
  59. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009; 102: 248-257.
  60. Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74: 213-220. DOI:10.1253/circj.CJ-09-0706
  61. Sachais BS, Turrentine T, Dawicki McKenna JM, et al. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice. Thromb Haemost 2007; 98: 1108-1113.
  62. Weyrich AS, Schwertz H, Kraiss LW, et al. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost 2009; 7: 241-246. DOI:10.1111/j.1538-7836.2008.03211.x
  63. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154: 485-490. DOI:10.1083/jcb.200105058
  64. Weyrich AS, Denis MM, Schwertz H, et al. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007; 109: 1975-1983. DOI:10.1182/blood-2006-08-042192
  65. Evangelista V, Manarini S, Di Santo A, et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006; 98: 593-595. DOI:10.1161/01.RES.0000214553.37930.3e
  66. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186. DOI:10.1016/j.cell.2007.01.037
  67. Langer HF, Gawaz M. Platelets in regenerative medicine. Basic Res Cardiol 2008; 103: 299-307. DOI:10.1007/s00395-008-0721-4
  68. Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12: 557-567. DOI:10.1038/nm1400
  69. Stellos K, Bigalke B, Langer H, et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J 2009; 30: 584-593. DOI:10.1093/eurheartj/ehn566
  70. Hristov M, Zernecke A, Bidzhekov K, et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; 100: 590-597. DOI:10.1161/01.RES.0000259043.42571.68
  71. Mause SF, Ritzel E, Liehn EA, et al. Platelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. Circulation 122: 495-506.
  72. Koenen RR, Weber C. Platelet-derived chemokines in vascular remodeling and atherosclerosis. Semin Thromb Hemost 36: 163-169.
  73. Langer H, May AE, Daub K, et al. Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro. Circ Res 2006; 98: e2-10. DOI:10.1161/01.RES.0000201285.87524.9e
  74. Seizer P, Schiemann S, Merz T, et al. CD36 and macrophage scavenger receptor a modulate foam cell formation via inhibition of lipid-laden platelet phagocytosis. Semin Thromb Hemost 36: 157-162.

You may also be interested in...

 1.
COX-2 inhibitors and cardiovascular risk - Inferences based on biology and clinical studies

Muhammad R. Marwali, Jawahar L. Mehta

Thromb Haemost 2006 96 4: 401-406

http://dx.doi.org/10.1160/TH06-07-0385
2.
Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells

Online Supplementary Material

R. Suades (1, 2), T. Padró (1, 2), R. Alonso (3), P. Mata (3), L. Badimon (1, 2, 4)

Thromb Haemost 2013 110 2: 366-377

http://dx.doi.org/10.1160/TH13-03-0238
3.
C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor α, on human monocytes
Didier Hanriot1,2*, Gaëlle Bello1,2*, Armelle Ropars 1,2, Carole Seguin-Devaux 5, Gaël Poitevin 1,2, Sandrine Grosjean 3, Véronique Latger-Cannard2,3,4, Yvan Devaux 1,2, 5, Faiez Zannad 1,2, Véronique Regnault2,4, Patrick Lacolley 1,2, Paul-Michel Mertes 1,2, Ketsia Hess* 1,2, Dan Longrois*1,2

Thromb Haemost 2008 99 3: 558-569

http://dx.doi.org/10.1160/TH07-06-0410